MMIT Reality Check on Non-Small Cell Lung Cancer BRAF+ (May 2021)

According to our recent payer coverage analysis for non-small cell lung cancer BRAF+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for non-small cell lung cancer BRAF+ treatments shows that under the pharmacy benefit, about 71% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: Coverage is under the pharmacy benefit. Prior authorization is required for both Mekinist and Tafinlar to ensure appropriate use. Payer policies for lung cancer typically follow National Comprehensive Cancer Network (NCCN) guidelines.

by Matt Breese

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

young-women-hand-scratch-the-itch-on-the-arm-healthcare-and-medicine
May 20

MMIT Reality Check on Atopic Dermatitis

Read More
May 13

MMIT Reality Check on Narcolepsy

Read More
nurse-doing-blood-test
May 6

MMIT Reality Check on Hemophilia B (Factor IX)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today